L
Longboard Pharmaceuticals
A clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases
About Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to creating transformative medicines for neurological diseases, with a particular focus on rare conditions. The company leverages over 20 years of research in G protein-coupled receptors (GPCRs) to develop next-generation treatments. Longboard's pipeline includes innovative compounds like bexicaserin, aimed at treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs), a group of severe epilepsies characterized by drug-resistant seizures and significant developmental delays. The company operates in the biopharmaceutical market, targeting healthcare providers and patients affected by neurological and rare diseases. Longboard's business model involves advancing its drug candidates through clinical trials, securing regulatory approvals, and eventually commercializing these therapies. Revenue is generated through partnerships, licensing agreements, and future product sales.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2020
- Headquarters
- San Diego, United States
- Listing
- IPO 2021
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 29.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2024 | $2.6B | $2.6B | Lundbeck | ↗ |
| POST IPO EQUITYOther financing | Jan 2024 | $242M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$57M | — |
| 2025 | $0 | — | −$57M | — |
| 2024 | $0 | — | −$57M | — |
| 2023 | $0 | — | −$57M | — |
| 2022 | $0 | — | −$45M | — |
| 2021 | $0 | — | −$28M | — |
| 2020 | $0 | — | −$14M | — |
Growth signals
Latest recorded traffic for Longboard Pharmaceuticals is 1.2K monthly website visits, up 224.3% over the last three months. Longboard Pharmaceuticals's team declined 72.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Cormorant Asset Management
Highside Capital Management
Farallon Capital Management
Arena Pharmaceuticals
T. Rowe Price
Other known investors1 additional known investor
Lundbeck
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Longboard Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Longboard Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.